Clinical evidence on the anti-cancer effects of metformin is still evolving. While some retrospective studies and observational data are promising, randomized controlled trials (RCTs) are crucial for definitive conclusions. Several RCTs are currently underway to assess the efficacy of metformin as an adjuvant therapy in various cancers.
